Insider Selling: Insmed (NASDAQ:INSM) COO Sells 791 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 791 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total value of $123,530.47. Following the completion of the transaction, the chief operating officer owned 106,810 shares in the company, valued at $16,680,517.70. This represents a 0.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Roger Adsett also recently made the following trade(s):

• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $358,616.03.
• On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total value of $140,406.14.
• On Tuesday, January 6th, Roger Adsett sold 1,429 shares of Insmed stock. The shares were sold at an average price of $173.33, for a total transaction of $247,688.57.

Insmed Price Performance

Insmed stock traded down $4.72 during mid-day trading on Wednesday, hitting $152.44. 1,794,597 shares of the company traded hands, compared to its average volume of 2,638,682. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. Insmed, Inc. has a one year low of $60.40 and a one year high of $212.75. The stock has a market cap of $32.51 billion, a price-to-earnings ratio of -24.63 and a beta of 1.11. The stock has a fifty day moving average price of $178.14 and a 200-day moving average price of $159.71.

Analysts Set New Price Targets

INSM has been the topic of a number of research analyst reports. Barclays began coverage on Insmed in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 target price on the stock. Cantor Fitzgerald increased their price objective on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Redburn Partners set a $263.00 target price on Insmed in a research report on Thursday, December 4th. UBS Group cut their target price on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th. Finally, Royal Bank Of Canada lifted their price target on shares of Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $206.04.

Institutional Trading of Insmed

Several hedge funds and other institutional investors have recently bought and sold shares of INSM. CIBC Private Wealth Group LLC grew its holdings in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. Kingsview Wealth Management LLC boosted its position in Insmed by 2.7% during the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 60 shares during the period. Choreo LLC boosted its position in Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 65 shares during the period. ORG Partners LLC grew its holdings in Insmed by 12.7% in the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 74 shares during the last quarter. Finally, Spire Wealth Management increased its position in shares of Insmed by 11.5% in the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 80 shares during the period.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.